Kukje Pharma Co., Ltd. (KRX:002720)
South Korea · Delayed Price · Currency is KRW 4,870.00
+85.00 (1.78%)
Apr 1, 2026, 3:30 PM KST
Kukje Pharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 5,698 | 5,205 | -8,415 | 3,557 | -1,559 |
Depreciation & Amortization | 3,226 | 3,203 | 4,204 | 4,488 | 4,419 |
Asset Writedown & Restructuring Costs | 20 | 30.13 | 1,874 | 502.66 | - |
Loss (Gain) From Sale of Investments | 185.97 | 180.1 | -22.11 | 16.73 | -13.21 |
Loss (Gain) on Equity Investments | - | - | - | -23.21 | 72.91 |
Provision & Write-off of Bad Debts | -464.69 | 349.37 | -1,249 | -1,313 | -1,288 |
Other Operating Activities | 2,517 | 3,111 | 1,755 | 3,550 | 2,369 |
Change in Accounts Receivable | -4,503 | -2,334 | 565.75 | 4,648 | 4,595 |
Change in Inventory | -2,882 | -949.39 | 1,290 | -4,789 | 3,261 |
Change in Accounts Payable | 6,070 | -4,396 | 11,579 | 711.15 | 933.17 |
Change in Other Net Operating Assets | -4,032 | -458.16 | -8,006 | -4,845 | -3,192 |
Operating Cash Flow | 5,835 | 3,940 | 3,575 | 6,504 | 9,597 |
Operating Cash Flow Growth | 48.11% | 10.20% | -45.03% | -32.23% | 88.18% |
Capital Expenditures | -3,619 | -2,911 | -1,046 | -1,259 | -1,892 |
Sale of Property, Plant & Equipment | 12.48 | 110.35 | 305.74 | 81.44 | 23.36 |
Sale (Purchase) of Intangibles | -249.66 | -5.73 | - | -18 | -68.5 |
Investment in Securities | -433.24 | -1,746 | 190 | - | -1,361 |
Other Investing Activities | 133.36 | -207.63 | -624.89 | -151.54 | -83.05 |
Investing Cash Flow | -4,156 | -4,760 | -1,175 | -1,347 | -3,382 |
Short-Term Debt Issued | 8,000 | 10,500 | 7,900 | - | - |
Total Debt Issued | 8,000 | 10,500 | 7,900 | - | - |
Short-Term Debt Repaid | -7,000 | -11,500 | -4,900 | -7,000 | -2,000 |
Long-Term Debt Repaid | -183.99 | -197.65 | -358.95 | -433.03 | -388.36 |
Total Debt Repaid | -7,184 | -11,698 | -5,259 | -7,433 | -2,388 |
Net Debt Issued (Repaid) | 816.01 | -1,198 | 2,641 | -7,433 | -2,388 |
Issuance of Common Stock | 138.74 | - | - | - | - |
Repurchase of Common Stock | - | - | -31.07 | -40.62 | -45.54 |
Dividends Paid | -610.88 | - | - | - | - |
Other Financing Activities | -0 | 0 | 0 | 0 | 0 |
Financing Cash Flow | 343.87 | -1,198 | 2,610 | -7,474 | -2,434 |
Foreign Exchange Rate Adjustments | 1.66 | 105.87 | 40.82 | -10.38 | 71.65 |
Net Cash Flow | 2,025 | -1,911 | 5,051 | -2,327 | 3,853 |
Free Cash Flow | 2,216 | 1,029 | 2,529 | 5,245 | 7,705 |
Free Cash Flow Growth | 115.42% | -59.32% | -51.78% | -31.93% | - |
Free Cash Flow Margin | 1.26% | 0.66% | 1.87% | 4.14% | 6.43% |
Free Cash Flow Per Share | 108.92 | 50.60 | 124.88 | 258.88 | 380.18 |
Cash Interest Paid | 930.69 | 1,220 | 1,418 | 1,003 | 722.5 |
Cash Income Tax Paid | 1,962 | 1,562 | 2,269 | -559.71 | 2,491 |
Levered Free Cash Flow | -247.66 | -3,135 | 8,550 | 3,504 | 5,485 |
Unlevered Free Cash Flow | 320.1 | -2,381 | 9,450 | 4,129 | 5,920 |
Change in Working Capital | -5,347 | -8,138 | 5,429 | -4,274 | 5,597 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.